We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Humacyte, Inc. (HUMA) Laps the Stock Market: Here's Why
Read MoreHide Full Article
Humacyte, Inc. (HUMA - Free Report) closed at $1.72 in the latest trading session, marking a +1.18% move from the prior day. The stock's change was more than the S&P 500's daily gain of 0.53%. Elsewhere, the Dow saw an upswing of 0.52%, while the tech-heavy Nasdaq appreciated by 0.52%.
Heading into today, shares of the company had lost 5.03% over the past month, lagging the Medical sector's gain of 2.87% and the S&P 500's gain of 0.71%.
The investment community will be closely monitoring the performance of Humacyte, Inc. in its forthcoming earnings report. The company is predicted to post an EPS of -$0.17, indicating a 48.48% growth compared to the equivalent quarter last year.
HUMA's full-year Zacks Consensus Estimates are calling for earnings of -$0.35 per share and revenue of $3.51 million. These results would represent year-over-year changes of +66.67% and 0%, respectively.
Investors should also take note of any recent adjustments to analyst estimates for Humacyte, Inc. Such recent modifications usually signify the changing landscape of near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, there's been no change in the Zacks Consensus EPS estimate. Humacyte, Inc. is currently a Zacks Rank #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 83, which puts it in the top 34% of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Humacyte, Inc. (HUMA) Laps the Stock Market: Here's Why
Humacyte, Inc. (HUMA - Free Report) closed at $1.72 in the latest trading session, marking a +1.18% move from the prior day. The stock's change was more than the S&P 500's daily gain of 0.53%. Elsewhere, the Dow saw an upswing of 0.52%, while the tech-heavy Nasdaq appreciated by 0.52%.
Heading into today, shares of the company had lost 5.03% over the past month, lagging the Medical sector's gain of 2.87% and the S&P 500's gain of 0.71%.
The investment community will be closely monitoring the performance of Humacyte, Inc. in its forthcoming earnings report. The company is predicted to post an EPS of -$0.17, indicating a 48.48% growth compared to the equivalent quarter last year.
HUMA's full-year Zacks Consensus Estimates are calling for earnings of -$0.35 per share and revenue of $3.51 million. These results would represent year-over-year changes of +66.67% and 0%, respectively.
Investors should also take note of any recent adjustments to analyst estimates for Humacyte, Inc. Such recent modifications usually signify the changing landscape of near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, there's been no change in the Zacks Consensus EPS estimate. Humacyte, Inc. is currently a Zacks Rank #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 83, which puts it in the top 34% of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.